Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

摘要

An approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B. burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.